Dendreon Says Prelim. Data from LT Phase II STAND Study Will Be Presented at EAU Congress, Will Show Immune Responses with PROVENGE Enhanced, Sustained
April 11, 2014 at 07:02 AM EDT
Dendreon Corporation (NASDAQ: DNDN) today announced the presentation of preliminary data from a long-term analysis of the Phase ...